Share Name Share Symbol Market Type Share ISIN Share Description
Northw.Bio Regs LSE:NWBS London Ordinary Share USU666161000 COM SHS USD0.001 (REGS)
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 13.00p 0 06:32:19
Bid Price Offer Price High Price Low Price Open Price
0.00p 0.00p - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 6.23

Northw.Bio Regs (NWBS) Latest News

Real-Time news about Northw.Bio Regs (London Stock Exchange): 0 recent articles
More Northw.Bio Regs News
Northw.Bio Regs Takeover Rumours

Northw.Bio Regs (NWBS) Share Charts

1 Year Northw.Bio Regs Chart

1 Year Northw.Bio Regs Chart

1 Month Northw.Bio Regs Chart

1 Month Northw.Bio Regs Chart

Intraday Northw.Bio Regs Chart

Intraday Northw.Bio Regs Chart

Northw.Bio Regs (NWBS) Discussions and Chat

Northw.Bio Regs Forums and Chat

Date Time Title Posts
17/7/200911:13Nationwide BS INCREASES mortgages 0.5%! 6 Aug 034
11/11/200810:32Northwest bio.di.149

Add a New Thread

Northw.Bio Regs (NWBS) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Northw.Bio Regs trades in real-time

Northw.Bio Regs (NWBS) Top Chat Posts

andrbea: interesting to see the latent effect of a new drug for prostrate cancer would have on a share price compare this story from March 2007 caused a 250% pre-market spike...
andrbea: While there has been tremendous hype and controversy surrounding companies developing cancer vaccines, including Dendreon (DNDN) and Cell Genesys (CEGE), a tiny Swiss biotech company took center stage on Monday. Northwest BioTherapeutics (NWBO.OB) announced that the Swiss Institute of Public Health had cleared its dendretic-cell vaccine, DCVax®-Brain, for commercial launch for treatment of brain cancer So, it is possible that the company will produce the vaccine in the U.S., and end up selling it to Americans in Switzerland, at much higher prices! The company is currently conducting Phase II trials in both the U.S. and EU, but expects final results by end of 2008. The company is also cleared to investigate its DCVax® Technology platform in various other cancers, including a phase III trial for prostate cancer. This should make Dendreon investors a little nervous. The company's DCVax® Technology has tremendous advantages over competing cancer vaccine platforms. /.. Even following Monday's jump in share price, the company still has a tiny market cap of only $32 million. If you thought Dendreon shares are wild, think again!
Northw.Bio Regs share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20180323 11:16:24